Actinium Pharmaceuticals

OverviewSuggest Edit

Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers. Its targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. Actinium is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

TypePublic
Founded2000
HQNew York, US
Websiteactiniumpharma.com

Latest Updates

Employees (est.) (Mar 2019)30(+20%)
Revenue (FY, 2011)$0
Share Price (Mar 2020)$0.2 (+5%)

Key People/Management at Actinium Pharmaceuticals

Sandesh Seth

Sandesh Seth

Chief Executive Officer and Chairman of the Board
Ajit Shetty

Ajit Shetty

Director
Mark Berger

Mark Berger

Chief Medical Officer
Richard L. Steinhart

Richard L. Steinhart

Director
Dale L. Ludwig

Dale L. Ludwig

Chief Scientific Officer
Jeffrey W. Chell

Jeffrey W. Chell

Director
Show more

Actinium Pharmaceuticals Office Locations

Actinium Pharmaceuticals has an office in New York
New York, US (HQ)
275 Madison Ave
Show all (1)

Actinium Pharmaceuticals Financials and Metrics

Actinium Pharmaceuticals Revenue

USD

Net income (Q3, 2019)

(6.6m)

EBIT (Q3, 2019)

(6.7m)

Market capitalization (27-Mar-2020)

32.4m

Closing stock price (27-Mar-2020)

0.2

Cash (30-Sept-2019)

14.3m

EV

18.2m
Actinium Pharmaceuticals's current market capitalization is $32.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

Cost of goods sold

Gross profit

General and administrative expense

337.04.5m3.9m10.2m11.5m9.3m9.2m6.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

Cost of goods sold

Gross profit

General and administrative expense

1.0k933.1k966.4k830.7k1.7m2.4m3.3m3.8m3.6m1.8m2.2m2.8m1.4m3.3m2.8m1.7m1.9m1.6m2.0m1.4m1.1m1.8m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

150.05.6m5.5m6.7m25.6m20.5m17.4m

Accounts Receivable

2.1b

Prepaid Expenses

167.1k218.4k699.9k803.5k

Inventories

1.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

150.0150.0150.0142.03.2m5.7m4.0m5.9m14.7m11.8m19.3m26.0m24.8m22.2m20.5m15.5m17.1m11.5m20.5m26.8m21.5m14.8m9.9m19.5m14.3m

Prepaid Expenses

117.1k84.3k53.0k667.9k608.1k671.9k634.0k257.5k157.6k937.1k922.7k1.6m1.0m1.0m673.0k299.6k336.2k189.9k

Inventories

Current Assets

150.0150.0150.0142.03.4m5.7m4.0m6.5m15.3m12.4m19.9m26.2m24.9m23.2m21.4m17.1m18.1m12.5m21.2m27.6m22.1m15.2m10.3m19.9m14.6m
USDY, 2019

EV/EBIT

-2.7 x

EV/CFO

-1.1 x

Financial Leverage

1.6 x
Show all financial metrics

Actinium Pharmaceuticals Online and Social Media Presence

Embed Graph

Actinium Pharmaceuticals News and Updates

Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting

NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted new data from a Phase 1 trial studying Actimab-A in combination with the salvage chemotherapy regimen CLAG-M that was presented in a poster presentation at the 61st...

Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax

NEW YORK, Oct. 30, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that the next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program, after successful completion of the Actimab-A phase 2 trial in Acute...

Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

NEW YORK, Oct. 26, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) will host a conference call and webinar today at 11:00 AM ET to provide key updates on the advancement of its CD33 program that is based on the Antibody RadiationConjugate (ARC), Ac-225 –...

Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that it will host a conference call and webinar to provide key updates on the advancement of its CD33 program on Friday, October 26, 2018 at 11:00 AM ET. Actinium's CD33 program...

Actinium Pharmaceuticals Blogs

Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia

- 86% complete remission rate with 71% of patients achieving negative minimal residual disease status with a sub-therapeutic dose of Actimab-A with CLAG-M in second dose cohort of early stage safety trial - Preliminary remission rates achieved with Actimab-A combined with CLAG-M compare favorably to…

Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)

- Substantially lower rates of febrile neutropenia and sepsis in patients receiving Iomab-B compared to patients receiving salvage chemotherapy in the control arm - 78 percent of patients in the Iomab-B arm are potentially evaluable for the primary endpoint compared to 13 percent in the control ar…

Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation

- 77% of all participating patients who are typically considered ineligible have received a bone marrow transplant in the SIERRA trial, the only randomized Phase 3 trial to offer potentially curative allogeneic transplant to older patients with active, relapsed or refractory AML - 100% of patients…

Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

- Presentation scheduled for Tuesday, February 11th at 10:15 am ET NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that Sandesh Seth, Actinium's Chairman & CEO, will be presenting at the 22nd Annual BIO CEO & Invest…

Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma

- Trial will replace currently used chemotherapy conditioning with apamistamab-I-131, Actinium's targeted conditioning ARC, to selectively eliminate lymphoma cancer cells and stem cells to enable engraftment of stem cell gene therapy - Anti-HIV stem cell gene therapy intended to simultaneously tre…

Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase™

- Presentation scheduled for Monday, January 13 at 2:30 pm PT NEW YORK, Jan. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") announced today that Sandesh Seth, Actinium's Chairman and CEO, will present at the 2020 Biotech Showcase™ being held on January…
Show more

Actinium Pharmaceuticals Frequently Asked Questions

  • When was Actinium Pharmaceuticals founded?

    Actinium Pharmaceuticals was founded in 2000.

  • Who are Actinium Pharmaceuticals key executives?

    Actinium Pharmaceuticals's key executives are Sandesh Seth, Ajit Shetty and Mark Berger.

  • How many employees does Actinium Pharmaceuticals have?

    Actinium Pharmaceuticals has 30 employees.

  • Who are Actinium Pharmaceuticals competitors?

    Competitors of Actinium Pharmaceuticals include LabConnect, Akrivis Technologies and Lionex.

  • Where is Actinium Pharmaceuticals headquarters?

    Actinium Pharmaceuticals headquarters is located at 275 Madison Ave, New York.

  • Where are Actinium Pharmaceuticals offices?

    Actinium Pharmaceuticals has an office in New York.

  • How many offices does Actinium Pharmaceuticals have?

    Actinium Pharmaceuticals has 1 office.